What Is Bioglutide (NA-931)? How It Compares to Retatrutide

Bioglutide (also written NA-931) and retatrutide are often lumped together — but they are not the same molecule. If you've searched for "bioglutide," this guide explains what the compound actually is, how it differs from retatrutide, and what to look for when sourcing GLP-family peptides for research.

Everything below is provided for research context only. These are laboratory research compounds — not medicines, and nothing here is medical or dosing advice.

What Is Bioglutide (NA-931)?

Bioglutide, referenced in the research community as NA-931, is an investigational metabolic compound. Unlike the injectable incretin peptides, it is described as an orally active, once-daily agent, and it is reported to engage four receptor targets rather than three:

• GLP-1 receptor (glucagon-like peptide-1)
• GIP receptor (glucose-dependent insulinotropic polypeptide)
• Glucagon receptor
• IGF-1 receptor — the target that sets it apart, studied in the context of preserving lean mass

That fourth target is why it's informally nicknamed a "GLP-4" agonist. It is early-stage and, importantly, thinly characterized in the research-supply market — there is far less public, peer-reviewed data on it than on the established incretin peptides.

Bioglutide vs. Retatrutide: The Key Difference

The compound bioglutide is most often confused with is retatrutide (LY3437943). They overlap on three targets but are genuinely different molecules:

• Targets: Bioglutide is reported to hit four receptors (GLP-1, GIP, glucagon, IGF-1); retatrutide is a triple agonist (GLP-1, GIP, glucagon) — no IGF-1 arm.
• Route: Bioglutide is described as oral; retatrutide is an injectable peptide.
• Evidence base: Retatrutide has extensive published phase-2 research; bioglutide/NA-931 remains investigational with limited public characterization.

In short: retatrutide is the closest widely-researched, COA-tested compound to what most "bioglutide" searches are after — it shares three of the four targets — but it is not a substitute, and it is not the same thing.

What the Retatrutide Research Shows

Because retatrutide is the far better-characterized of the two, it's where the real literature sits. As a triple agonist it has been studied for metabolic endpoints in randomized phase-2 research, with published trials reporting substantial changes in body weight and metabolic markers over 24–48 weeks. These are research findings from clinical studies, reported here for scientific context — not outcomes we claim or endorse, and not medical advice.

Sourcing GLP-Family Research Peptides: What to Look For

Coined marketing names like "bioglutide" can make it hard to know what's actually in a vial. For research you can trust, insist on:

• A named, characterized compound — an identifiable name, sequence, and CAS number, not just a brand label.
• A lot-matched Certificate of Analysis — HPLC purity and mass-spec identity for the exact lot you receive. (See how to read a COA.)
• Independent, accredited testing (ISO/IEC 17025) you can verify.
• Proper cold handling and clear research-use-only positioning.

Golden State Bio stocks retatrutide and GLP-1 S for research — each lot third-party tested with a COA. We do not list "bioglutide": until a compound is properly characterized and testable, we'd rather point you to one that is.

Frequently Asked Questions

Is bioglutide the same as retatrutide?

No. Bioglutide (NA-931) is an investigational, orally-described compound reported to target four receptors including IGF-1. Retatrutide (LY3437943) is an injectable triple agonist targeting GLP-1, GIP, and glucagon — three of the four. They share targets but are different molecules.

What does bioglutide target?

It is reported to engage GLP-1, GIP, glucagon, and IGF-1 receptors — the IGF-1 target is what earns it the informal "GLP-4" nickname. Retatrutide, by contrast, targets only the first three.

Can I buy bioglutide for research?

Bioglutide/NA-931 is investigational and thinly characterized in the supply market, which makes verifying identity and purity difficult. The closest widely-researched, COA-tested compound available is retatrutide. Golden State Bio carries retatrutide and GLP-1 S for research, not bioglutide.

Is retatrutide approved for human use?

No. Retatrutide is a research compound supplied for laboratory use only. It is not a medicine, is not approved for human or veterinary use, and nothing here is medical advice.

How do I verify a GLP peptide's identity and purity?

Rely on a lot-matched Certificate of Analysis showing HPLC purity and mass-spec identity from an accredited (ISO/IEC 17025) lab — not the product name on the label.